Consistently, lung cancer patients with high IL-6 expression displayed significantly shorter disease-free survival (DFS) (Fig. 1B) and overall survival (OS) (Fig. 1C) than those having lower IL-6 expression. This evidence concerns the gene IL6 and lung carcinoma.